AZNAstraZenecaRunning, no new patients
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer, Early Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 5,511 (final count)
- Started
- Oct 5, 2023
- Main results expected
- Mar 4, 2030
- Fully finished
- May 6, 2037
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive breast cancer-free survival (IBCFS)
Measured over: Up to 14 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05952557 · record last updated 2026-08-10 · checked 2026-11-09 15:47 UTC